Analytical Data
-
Gene name
TIM-3/HAVCR2
- Application
-
Alternative Names
Hepatitis A virus cellular receptor 2 homolog; HAVcr-2; T-cell immunoglobulin and mucin domain-containing protein 3; T-cell immunoglobulin mucin receptor 3; T-cell membrane protein 3; Tim3; Timd3
-
Species
Mouse
-
Source
HEK293
-
Tag
C- Fc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8VIM0
-
Expression Region
20-191aa
-
Molecular Weight
46.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), also known as HAVCR2, is a transmembrane protein that plays a crucial role in regulating immune responses, particularly in T-cell function and activation. It is predominantly expressed on exhausted T cells and various immune cells, and its interaction with ligands like galectin-9 has been implicated in promoting immune tolerance and inhibiting anti-tumor immunity. The study of TIM-3/HAVCR2 as a therapeutic target has gained significant attention in recent years, especially in the context of cancer immunotherapy, autoimmune diseases, and chronic infections. Dysregulation of TIM-3 expression is often associated with poor clinical outcomes in cancer patients, as tumor cells exploit this pathway to evade immune surveillance. Consequently, the development of TIM-3/HAVCR2 recombinant proteins for research and therapeutic applications aims to enhance our understanding of its biological mechanisms and potential as a checkpoint inhibitor. These studies may provide insights into combination therapies that invigorate the immune system, thereby improving the efficacy of existing cancer treatments. Through the exploration of TIM-3/HAVCR2 recombinant proteins, researchers aim to elucidate their roles in immune modulation and offer promising avenues for novel therapeutic strategies.
